Article Text

PDF
Review: Cholinesterase inhibitors and memantine consistently but marginally improve symptoms of dementia

Statistics from Altmetric.com

QUESTION

Question:

How effective are cholinesterase inhibitors and memantine for dementia?

Outcomes:

Cognitive and global functioning, behaviour, and quality of life measures such as activities of daily living and caregiver burden. Secondary outcomes: mortality, rate of institutionalisation, and adverse events.

METHODS

Design:

Systematic review with meta-analysis

Data sources:

MEDLINE, Pre-MEDLINE, EMBASE, PsycINFO, Cochrane Central Register of Controlled Trials, Allied and Complementary Medicine Database, CINAHL and AgeLine were searched from January 1986 to November 2006 for English language articles. Reference lists of identified studies were hand searched.

Study selection and analysis:

RCTs of cholinesterase inhibitors or memantine in people with major dementia (including Alzheimer’s, vascular and Parkinson’s dementia) compared to placebo or another drug. Measures of cognition were the Alzheimer’s Disease Assessment Scale (ADAS; cognitive and non-cognitive subscales), Severe Impairment Battery (SIB), and Mini-Mental State Examination. The validated measure of global functioning was the clinician-based impression of change with caregiver input (CIBIC-plus). Heterogeneity was investigated using the I2 statistic.

MAIN RESULTS

Fifty nine RCTs (96 publications) were identified which met inclusion criteria (donepezil vs …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.